Innovative Biotech Solutions

---

ATAP Therapeutics is a U.S. company with initial technology invented by and licensed from Rutgers University. We were formed with the vision of combining the dynamic, creative, and collaborative culture with a will to overcome cancer resistance to benefit patients. We'll develop innovative therapies based on clear differentiation and rigorous data to satisfy high unmet medical needs. 

Advanced solid tumor cancers are types of cancer that have spread beyond the primary cancer site. 

The tumors in these advanced cancers can also recur after treatment. These solid cancers are often more difficult to treat in patients than cancer with an earlier stage tumor because they have progressed further.

Typical treatment options for patients with advanced solid tumors may include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Our leading agent ATAP-M8 is designed to enable more effective tumor-targeted, tissue-penetrating delivery of anti-cancer ATAP for apoptosis of mitochondria. The ATAP Platform has the potential to revolutionize the way we treat advanced solid tumors and could ultimately lead to more successful outcomes for patients.